SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 575.56 |
| Enterprise Value ($M) | 807.31 |
| Book Value ($M) | 34.02 |
| Book Value / Share | 1.16 |
| Price / Book | 16.92 |
| NCAV ($M) | -24.92 |
| NCAV / Share | -0.85 |
| Price / NCAV | -23.10 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.37 |
| Return on Assets (ROA) | -0.35 |
| Return on Equity (ROE) | -2.94 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 8.25 |
| Current Ratio | 8.25 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 363.11 |
| Assets | 422.05 |
| Liabilities | 388.03 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 91.28 |
| Operating Income | -114.95 |
| Net Income | -145.23 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -135.34 |
| Cash from Investing | 95.40 |
| Cash from Financing | 127.05 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vanguard Group Inc | 4.94 | 9.94 | |
| 13G/A | BlackRock, Inc. | 6.20 | -25.41 | |
| 13G | First Light Asset Management, LLC | 15.17 | ||
| 13G | Point72 Asset Management, L.P. | 5.60 | 114.49 | |
| 13G/A | Frazier Life Sciences Public Fund, L.P. | 5.40 | -13.66 | |
| 13G/A | Fairmount Funds Management LLC | 0.00 | ||
| 13G/A | Deep Track Capital, LP | 0.00 | -100.00 | |
| 13G/A | Tang Capital Management Llc | 4.40 | ||
| 13D/A | EcoR1 Capital, LLC | 25.80 | 3.65 | |
| 13G | Fmr Llc | 10.51 | 1,515.07 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 49,278 | 377,178 | 13.06 | |
| 85,468 | 510,234 | 16.75 | |
| 98,790 | 447,983 | 22.05 | |
| 149,338 | 567,556 | 26.31 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| AMLX – Amylyx Pharmaceuticals, Inc. | AMPH – Amphastar Pharmaceuticals, Inc. |
| AMRX – Amneal Pharmaceuticals, Inc. | ANNX – Annexon, Inc. |
| APLS – Apellis Pharmaceuticals, Inc. |
Financial data and stock pages provided by
Fintel.io